4 Ketoconazol – Den stærke CYP3A4/ 5- inhibitor ketoconazol øger den systemiske eksponering for lasofoxifen med 20%, hvilket ikke vurderes at være klinisk relevant.
4 Ketoconazole - The strong CYP3A4/ 5 inhibitor ketoconazole increased the systemic exposure of lasofoxifene by 20% which is not considered to be clinically meaningful.